Coherus is dedicated to advancing and commercializing a diverse range of next-generation immuno-oncology therapies aimed at improving patient survival across various tumor types. Coherus flagship brand LOQTORZI® (toripalimab-tpzi) is the latest of their three main brands to get FDA approval